Overview

• Bernstein reaffirmed an Outperform rating with a $1,100 price target and said it has greater confidence in orforglipron as the leading oral GLP-1.
• Lilly opened an 82,514-square-foot Gateway Labs hub in San Diego on September 26 that can host up to 15 startups and more than 250 employees as part of its Catalyze360 program.
• The company announced a $6.5 billion manufacturing site in Houston to scale small-molecule production, including orforglipron, with operations targeted within five years and several hundred new jobs.
• Lilly is preparing international expansion for orforglipron with plans to launch in India pending regulatory approval.
• Lilly streamlined its obesity pipeline by halting a bimagrumab study, while European regulators granted marketing authorization for the Alzheimer’s therapy donanemab.